CL2007003211A1 - Uso de tenecteplasa para reestablecer la funcion de un cateter disfuncional para hemodialisis permanente en un mamifero. - Google Patents

Uso de tenecteplasa para reestablecer la funcion de un cateter disfuncional para hemodialisis permanente en un mamifero.

Info

Publication number
CL2007003211A1
CL2007003211A1 CL200703211A CL2007003211A CL2007003211A1 CL 2007003211 A1 CL2007003211 A1 CL 2007003211A1 CL 200703211 A CL200703211 A CL 200703211A CL 2007003211 A CL2007003211 A CL 2007003211A CL 2007003211 A1 CL2007003211 A1 CL 2007003211A1
Authority
CL
Chile
Prior art keywords
tenecteplasa
hemodialisis
mammer
dysfunctional
catheter
Prior art date
Application number
CL200703211A
Other languages
English (en)
Spanish (es)
Inventor
Martha E Blaney
Original Assignee
Genentech Inc
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Genentech Inc filed Critical Genentech Inc
Publication of CL2007003211A1 publication Critical patent/CL2007003211A1/es

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61L—METHODS OR APPARATUS FOR STERILISING MATERIALS OR OBJECTS IN GENERAL; DISINFECTION, STERILISATION OR DEODORISATION OF AIR; CHEMICAL ASPECTS OF BANDAGES, DRESSINGS, ABSORBENT PADS OR SURGICAL ARTICLES; MATERIALS FOR BANDAGES, DRESSINGS, ABSORBENT PADS OR SURGICAL ARTICLES
    • A61L29/00—Materials for catheters, medical tubing, cannulae, or endoscopes or for coating catheters
    • A61L29/14—Materials characterised by their function or physical properties, e.g. lubricating compositions
    • A61L29/16—Biologically active materials, e.g. therapeutic substances
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K38/00—Medicinal preparations containing peptides
    • A61K38/16—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • A61K38/43—Enzymes; Proenzymes; Derivatives thereof
    • A61K38/46—Hydrolases (3)
    • A61K38/48—Hydrolases (3) acting on peptide bonds (3.4)
    • A61K38/49—Urokinase; Tissue plasminogen activator
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P7/00—Drugs for disorders of the blood or the extracellular fluid
    • A61P7/02—Antithrombotic agents; Anticoagulants; Platelet aggregation inhibitors
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P9/00—Drugs for disorders of the cardiovascular system
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N9/00—Enzymes; Proenzymes; Compositions thereof; Processes for preparing, activating, inhibiting, separating or purifying enzymes
    • C12N9/14—Hydrolases (3)
    • C12N9/48—Hydrolases (3) acting on peptide bonds (3.4)
    • C12N9/50—Proteinases, e.g. Endopeptidases (3.4.21-3.4.25)
    • C12N9/64—Proteinases, e.g. Endopeptidases (3.4.21-3.4.25) derived from animal tissue
    • C12N9/6421—Proteinases, e.g. Endopeptidases (3.4.21-3.4.25) derived from animal tissue from mammals
    • C12N9/6424—Serine endopeptidases (3.4.21)
    • C12N9/6456—Plasminogen activators
    • C12N9/6459—Plasminogen activators t-plasminogen activator (3.4.21.68), i.e. tPA
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12Y—ENZYMES
    • C12Y304/00—Hydrolases acting on peptide bonds, i.e. peptidases (3.4)
    • C12Y304/21—Serine endopeptidases (3.4.21)
    • C12Y304/21069—Protein C activated (3.4.21.69)
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61L—METHODS OR APPARATUS FOR STERILISING MATERIALS OR OBJECTS IN GENERAL; DISINFECTION, STERILISATION OR DEODORISATION OF AIR; CHEMICAL ASPECTS OF BANDAGES, DRESSINGS, ABSORBENT PADS OR SURGICAL ARTICLES; MATERIALS FOR BANDAGES, DRESSINGS, ABSORBENT PADS OR SURGICAL ARTICLES
    • A61L2300/00—Biologically active materials used in bandages, wound dressings, absorbent pads or medical devices
    • A61L2300/20—Biologically active materials used in bandages, wound dressings, absorbent pads or medical devices containing or releasing organic materials
    • A61L2300/252—Polypeptides, proteins, e.g. glycoproteins, lipoproteins, cytokines
    • A61L2300/254—Enzymes, proenzymes
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61L—METHODS OR APPARATUS FOR STERILISING MATERIALS OR OBJECTS IN GENERAL; DISINFECTION, STERILISATION OR DEODORISATION OF AIR; CHEMICAL ASPECTS OF BANDAGES, DRESSINGS, ABSORBENT PADS OR SURGICAL ARTICLES; MATERIALS FOR BANDAGES, DRESSINGS, ABSORBENT PADS OR SURGICAL ARTICLES
    • A61L2300/00—Biologically active materials used in bandages, wound dressings, absorbent pads or medical devices
    • A61L2300/40—Biologically active materials used in bandages, wound dressings, absorbent pads or medical devices characterised by a specific therapeutic activity or mode of action
    • A61L2300/42—Anti-thrombotic agents, anticoagulants, anti-platelet agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61M—DEVICES FOR INTRODUCING MEDIA INTO, OR ONTO, THE BODY; DEVICES FOR TRANSDUCING BODY MEDIA OR FOR TAKING MEDIA FROM THE BODY; DEVICES FOR PRODUCING OR ENDING SLEEP OR STUPOR
    • A61M1/00—Suction or pumping devices for medical purposes; Devices for carrying-off, for treatment of, or for carrying-over, body-liquids; Drainage systems
    • A61M1/14—Dialysis systems; Artificial kidneys; Blood oxygenators ; Reciprocating systems for treatment of body fluids, e.g. single needle systems for hemofiltration or pheresis
    • A61M1/28—Peritoneal dialysis ; Other peritoneal treatment, e.g. oxygenation
    • A61M1/285—Catheters therefor
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61M—DEVICES FOR INTRODUCING MEDIA INTO, OR ONTO, THE BODY; DEVICES FOR TRANSDUCING BODY MEDIA OR FOR TAKING MEDIA FROM THE BODY; DEVICES FOR PRODUCING OR ENDING SLEEP OR STUPOR
    • A61M25/00—Catheters; Hollow probes
    • A61M2025/0019—Cleaning catheters or the like, e.g. for reuse of the device, for avoiding replacement

Landscapes

  • Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Engineering & Computer Science (AREA)
  • Chemical & Material Sciences (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • General Health & Medical Sciences (AREA)
  • Organic Chemistry (AREA)
  • Biomedical Technology (AREA)
  • Medicinal Chemistry (AREA)
  • Zoology (AREA)
  • Genetics & Genomics (AREA)
  • Wood Science & Technology (AREA)
  • Public Health (AREA)
  • Veterinary Medicine (AREA)
  • Animal Behavior & Ethology (AREA)
  • Biochemistry (AREA)
  • General Engineering & Computer Science (AREA)
  • Epidemiology (AREA)
  • Molecular Biology (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Gastroenterology & Hepatology (AREA)
  • Biotechnology (AREA)
  • Immunology (AREA)
  • Microbiology (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • General Chemical & Material Sciences (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Hematology (AREA)
  • Diabetes (AREA)
  • Heart & Thoracic Surgery (AREA)
  • Cardiology (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
  • Enzymes And Modification Thereof (AREA)
  • Materials For Medical Uses (AREA)
  • Peptides Or Proteins (AREA)
  • Measuring Or Testing Involving Enzymes Or Micro-Organisms (AREA)
  • Medicines Containing Material From Animals Or Micro-Organisms (AREA)
CL200703211A 2006-11-07 2007-11-07 Uso de tenecteplasa para reestablecer la funcion de un cateter disfuncional para hemodialisis permanente en un mamifero. CL2007003211A1 (es)

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
US86475806P 2006-11-07 2006-11-07
US98348907P 2007-10-29 2007-10-29

Publications (1)

Publication Number Publication Date
CL2007003211A1 true CL2007003211A1 (es) 2008-05-30

Family

ID=39362326

Family Applications (1)

Application Number Title Priority Date Filing Date
CL200703211A CL2007003211A1 (es) 2006-11-07 2007-11-07 Uso de tenecteplasa para reestablecer la funcion de un cateter disfuncional para hemodialisis permanente en un mamifero.

Country Status (10)

Country Link
US (1) US8916148B2 (enExample)
EP (1) EP2086571A2 (enExample)
JP (1) JP5871449B2 (enExample)
AR (1) AR063603A1 (enExample)
CA (1) CA2668347C (enExample)
CL (1) CL2007003211A1 (enExample)
PE (2) PE20120639A1 (enExample)
TW (1) TW200826981A (enExample)
UY (1) UY30693A1 (enExample)
WO (1) WO2008070353A2 (enExample)

Families Citing this family (6)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
PL371760A1 (en) 2001-11-26 2005-06-27 Genentech, Inc. Catheter composition and uses thereof
US20070014779A1 (en) * 2002-11-14 2007-01-18 Genentech, Inc. Plasminogen activator variant formulations
CA2668347C (en) 2006-11-07 2017-06-20 Genentech, Inc. Tissue plasminogen activator variant uses
MY171723A (en) 2010-12-23 2019-10-24 Gennova Biopharmaceuticals Ltd Pharmaceutical compositions of tenecteplase
GB201415062D0 (en) * 2014-08-26 2014-10-08 Aplagon Oy Therapeutic
MX383595B (es) * 2014-10-21 2025-03-14 Gennova Biopharmaceuticals Ltd Proceso novedoso de purificacion para el aislamiento y produccion comercial de tnk-tpa recombinante (tenecteplasa)

Family Cites Families (46)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
FI831484A7 (fi) 1982-05-05 1983-11-06 Genentech Inc Ihmiskudoksen plasminogeenien aktivaattori.
US5000185A (en) 1986-02-28 1991-03-19 Cardiovascular Imaging Systems, Inc. Method for intravascular two-dimensional ultrasonography and recanalization
US5019096A (en) 1988-02-11 1991-05-28 Trustees Of Columbia University In The City Of New York Infection-resistant compositions, medical devices and surfaces and methods for preparing and using same
US5270198A (en) 1988-05-20 1993-12-14 Genentech, Inc. DNA molecules encoding variants of tissue plasminogen activators, vectors, and host cells
GB8820945D0 (en) 1988-09-07 1988-10-05 Smith & Nephew Medical articles
NZ230808A (en) 1988-10-24 1993-04-28 Squibb & Sons Inc Pharmaceutical compositions and combinations containing an angiotensin-converting enzyme inhibitor and a thrombolytic agent
AU7998091A (en) 1990-05-17 1991-12-10 Harbor Medical Devices, Inc. Medical device polymer
US5399158A (en) 1990-05-31 1995-03-21 The United States Of America As Represented By The Secretary Of The Army Method of lysing thrombi
US5363754A (en) 1991-09-03 1994-11-15 Grainco Queensland Co-Operative Association Limited Apparatus for preparing animal feedstuff from cotton seed
EP0786257B1 (en) 1992-06-03 2003-07-30 Genentech, Inc. Tissue plasminogen activator glycosylation variants with improved therapeutic properties
US5362754A (en) 1992-11-12 1994-11-08 Univ. Of Tx Md Anderson Cancer Center M-EDTA pharmaceutical preparations and uses thereof
US5688516A (en) 1992-11-12 1997-11-18 Board Of Regents, The University Of Texas System Non-glycopeptide antimicrobial agents in combination with an anticoagulant, an antithrombotic or a chelating agent, and their uses in, for example, the preparation of medical devices
DE69426604T2 (de) 1993-11-24 2001-05-10 Dupont Pharmaceuticals Co., Wilmington Isoxazoline und isoxazole derivate als fibrinogen rezeptor antagonisten
US5849736A (en) 1993-11-24 1998-12-15 The Dupont Merck Pharmaceutical Company Isoxazoline and isoxazole fibrinogen receptor antagonists
US5885967A (en) 1994-03-04 1999-03-23 Eli Lilly And Company Antithrombotic agents
US5509896A (en) 1994-09-09 1996-04-23 Coraje, Inc. Enhancement of thrombolysis with external ultrasound
US5556380A (en) 1995-04-05 1996-09-17 Duke University Method for removing fibrin sheaths from catheters
CA2178541C (en) 1995-06-07 2009-11-24 Neal E. Fearnot Implantable medical device
US5772640A (en) 1996-01-05 1998-06-30 The Trustees Of Columbia University Of The City Of New York Triclosan-containing medical devices
US5932299A (en) 1996-04-23 1999-08-03 Katoot; Mohammad W. Method for modifying the surface of an object
US5840733A (en) 1996-07-01 1998-11-24 Redcell, Canada, Inc. Methods and compositions for producing novel conjugates of thrombin inhibitors and endogenous carriers resulting in anti-thrombins with extended lifetimes
US5837688A (en) 1996-11-27 1998-11-17 Gelfand; Mathew I. Use of thrombolytic reagents for prevention of vascular disease
GB9626795D0 (en) 1996-12-23 1997-02-12 Geistlich Soehne Ag Combating infection in delivery systems
WO1998028326A1 (en) 1996-12-23 1998-07-02 Biochem Pharma Inc. Bicyclic thrombin inhibitors
US5981826A (en) 1997-05-05 1999-11-09 Georgia Tech Research Corporation Poly(vinyl alcohol) cryogel
JPH10328293A (ja) 1997-06-04 1998-12-15 Unitika Ltd 医療用具及びその製造方法
US6206914B1 (en) 1998-04-30 2001-03-27 Medtronic, Inc. Implantable system with drug-eluting cells for on-demand local drug delivery
US6166007A (en) 1998-07-02 2000-12-26 Sodemann; Klaus Antimicrobial locks comprising taurinamide derivatives and carboxylic acids and/or salts thereof
US6174537B1 (en) 1998-09-25 2001-01-16 Becton, Dickinson And Company Catheter flush solution and method for its use
AU3625500A (en) 1999-03-11 2000-09-28 Du Pont Pharmaceuticals Company Synergy between low molecular weight heparin and platelet aggregation inhibitors, providing a combination therapy for the prevention and treatment of various thromboembolic disorders
BR0010381A (pt) 1999-03-11 2002-02-05 Du Pont Pharm Co Método de tratamento da trombose em um mamìfero, e uso de uma combinação de (i) um inibidor do fator xa, e (ii) um composto selecionado do grupo que consiste em aspirina, tpa, um antagonista gpiib/iiia, heparina de baixo peso molecular e heparina
CA2302720C (en) 1999-03-29 2009-07-14 Ed Geistlich Sohne Ag Fur Chemische Industrie Anticoagulant/sterilizing compositions and methods
US6187768B1 (en) 1999-06-01 2001-02-13 Becton, Dickinson And Company Kit for flushing medical devices and method of preparation
EP1060747A3 (en) 1999-06-16 2001-12-05 New York Blood Center, Inc. Fibrin(ogen) degradation and clot lysis by fibrinolytic metalloproteinase
US6592564B2 (en) 1999-07-23 2003-07-15 Vasca, Inc. Methods and kits for locking and disinfecting implanted catheters
US6350251B1 (en) 2000-01-18 2002-02-26 Biolink Corporation Biocidal locks
US20010031981A1 (en) 2000-03-31 2001-10-18 Evans Michael A. Method and device for locating guidewire and treating chronic total occlusions
EP1284780B1 (en) 2000-05-10 2008-05-07 Ash Access Technology, Inc. A catheter lock solution including a photo-oxidant
WO2002017714A2 (en) 2000-08-25 2002-03-07 Organ Recovery Systems, Inc. Methods of thrombolytic organ treatment and repair
US20050215978A1 (en) * 2001-05-25 2005-09-29 Ash Stephen R Method of enhancing catheter patency using a citrate salt catheter lock solution
PL371760A1 (en) 2001-11-26 2005-06-27 Genentech, Inc. Catheter composition and uses thereof
US20070014779A1 (en) 2002-11-14 2007-01-18 Genentech, Inc. Plasminogen activator variant formulations
EP1442753B1 (en) * 2003-02-03 2007-02-21 Polaschegg, Hans-Dietrich, Dr.techn. Composition for the prevention of indwelling device related infection
US7696182B2 (en) * 2004-11-02 2010-04-13 Nd Partners, Llc Antimicrobial locking solutions comprising taurinamide derivatives and biologically acceptable salts and acids, with the addition of small concentrations of heparin
US7749529B2 (en) * 2005-02-08 2010-07-06 Ash Access Technology, Inc. Catheter lock solution comprising citrate and a paraben
CA2668347C (en) 2006-11-07 2017-06-20 Genentech, Inc. Tissue plasminogen activator variant uses

Also Published As

Publication number Publication date
WO2008070353A2 (en) 2008-06-12
TW200826981A (en) 2008-07-01
PE20120639A1 (es) 2012-05-26
CA2668347A1 (en) 2008-06-12
US8916148B2 (en) 2014-12-23
AR063603A1 (es) 2009-02-04
JP5871449B2 (ja) 2016-03-01
WO2008070353A3 (en) 2008-08-28
PE20081488A1 (es) 2008-10-30
CA2668347C (en) 2017-06-20
JP2010509229A (ja) 2010-03-25
EP2086571A2 (en) 2009-08-12
US20120270299A1 (en) 2012-10-25
UY30693A1 (es) 2008-05-02

Similar Documents

Publication Publication Date Title
BRPI0821668A2 (pt) Uso
HRP20151113T1 (xx) Herbicidni pripravak
DE602007000122D1 (de) Feststoffbatterie
EP1992348A4 (en) PHARMACEUTICAL COMBINATION
LU92389I2 (fr) Cystéamine
BRPI0716327A2 (pt) Composto de fenilpropionamida e uso
BRPI0808246A2 (pt) "fralda descartável".
SE0702067L (sv) Bestick
EP2193795A4 (en) AQUEOUS PHARMACEUTICAL COMPOSITION CONTAINING LATANOPROST
EP1897558A4 (en) SOLID PREPARATION
EP2178212A4 (en) LOGICAL ELEMENT
CL2007003211A1 (es) Uso de tenecteplasa para reestablecer la funcion de un cateter disfuncional para hemodialisis permanente en un mamifero.
FI20065657L (fi) Soodakattilan sulakourun puhdistin
BRPI0807989A2 (pt) Composto de éster e uso do mesmo.
DE602007001744D1 (de) Uhr
DK1954301T3 (da) Konfekture-sammensætninger med magnolia-barkekstrakt
FR2908109B1 (fr) Element de nacelle de turboreacteur
NL1033745A1 (nl) Sleepboot.
DE602006016553D1 (de) Umkehrbare Uhr
FR2904415B3 (fr) Cuillere de dosage.
ATE530164T1 (de) Wässrige pharmazeutische zubereitung
BRPI0823049A2 (pt) Anticorpos para glicoesfingolipídeos tipo 1 anti-estendidos, derivados dos mesmos e uso.
FIU20070173U0 (fi) Tuntoelin
FR2899083B1 (fr) Grille-pain
DE112006002119A5 (de) Tee-Eindrücker